{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:00:55Z","timestamp":1780491655632,"version":"3.54.1"},"reference-count":90,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"unspecified","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","award":["PRO18-6966"],"award-info":[{"award-number":["PRO18-6966"]}],"id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,6,10]]},"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Major depressive disorder (MDD) in people with advanced life-limiting illnesses can have significant impact on the quality-of-life of those affected. The management of MDD in the palliative care setting can be challenging as typical antidepressants may not work in time nor be tolerated due to coexisting organ dysfunctions, symptom burden and frailty. Parenteral ketamine was found to exhibit effective and rapid-onset antidepressant effect even against treatment-resistant depression in the psychiatric population. However, there is currently neither feasibility study nor available prospective study available to inform of the safety, tolerability and efficacy of such for MDD in the palliative setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This is an open-labelled, single arm, phase II pilot feasibility study involving adult patients with advanced life-limiting illnesses and MDD across four palliative care services in Australia. It has an individual dose-titration design (0.1\u20130.4\u2009mg\/kg) with weekly treatments of subcutaneous ketamine infusion over 2\u2009hours. The primary outcome is feasibility. The secondary outcomes are related to the safety, tolerability and antidepressant efficacy of ketamine, participants\u2019 satisfaction in relation to the trial process and the reasons for not completing the study at various stages. The feasibility data will be reported using descriptive statistics. Meanwhile, side effects, tolerability and efficacy data will be analysed using change of assessment scores from baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethics approval was acquired (South Western Sydney Local Health District: HREC\/18\/LPOOL\/466). The results of this study will be submitted for publication in peer-reviewed journals and presented at relevant conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>Australian New Zealand Clinical Trial Registry Number: ACTRN12618001586202; Pre-results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-052312","type":"journal-article","created":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T13:11:25Z","timestamp":1624885885000},"page":"e052312","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Study protocol for SKIPMDD: subcutaneous ketamine infusion in palliative care patients with advanced life limiting illnesses for major depressive disorder (phase II pilot feasibility study)"],"prefix":"10.1136","volume":"11","author":[{"given":"Wei","family":"Lee","sequence":"first","affiliation":[{"name":"Improving Care for Palliative Aged, and Chronic Care through Clinical Research and Translation (IMPACCT), Faculty of Health, University of Technology Sydney, Sydney, New South Wales, Australia"},{"name":"St Vincent\"s Clinical School, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Sheehan","sequence":"additional","affiliation":[{"name":"Calvary Hospital, Kogarah, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Chye","sequence":"additional","affiliation":[{"name":"Palliative Care, St Vincent\"s Hospital Sydney, Darlinghurst, New South Wales, Australia"},{"name":"University of Notre Dame, Darlinghurst, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungwon","family":"Chang","sequence":"additional","affiliation":[{"name":"Improving Care for Palliative Aged, and Chronic Care through Clinical Research and Translation (IMPACCT), Faculty of Health, University of Technology Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Loo","sequence":"additional","affiliation":[{"name":"Black Dog Institute, Randwick, New South Wales, Australia"},{"name":"Department of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Draper","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Agar","sequence":"additional","affiliation":[{"name":"Improving Care for Palliative Aged, and Chronic Care through Clinical Research and Translation (IMPACCT), Faculty of Health, University of Technology Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1988-1250","authenticated-orcid":false,"given":"David C","family":"Currow","sequence":"additional","affiliation":[{"name":"Improving Care for Palliative Aged, and Chronic Care through Clinical Research and Translation (IMPACCT), Faculty of Health, University of Technology Sydney, Sydney, New South Wales, Australia"},{"name":"Cancer Institute New South Wales, St Leonards, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,6,28]]},"reference":[{"key":"2025121400544593000_11.6.e052312.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70002-X"},{"key":"2025121400544593000_11.6.e052312.2","doi-asserted-by":"publisher","DOI":"10.1191\/0269216302pm507oa"},{"key":"2025121400544593000_11.6.e052312.3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jpainsymman.2020.07.011","article-title":"Clinically significant depressive symptoms are prevalent in people with extremely short Prognoses-A systematic review","volume":"61","author":"Lee","year":"2021","journal-title":"J Pain Symptom Manage"},{"key":"2025121400544593000_11.6.e052312.4","doi-asserted-by":"publisher","DOI":"10.1093\/geront\/48.5.593"},{"key":"2025121400544593000_11.6.e052312.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.22.2907"},{"key":"2025121400544593000_11.6.e052312.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(98)71325-8"},{"key":"2025121400544593000_11.6.e052312.7","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-132-3-200002010-00007"},{"key":"2025121400544593000_11.6.e052312.8","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19841115)54:10<2243::AID-CNCR2820541030>3.0.CO;2-V"},{"key":"2025121400544593000_11.6.e052312.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1408-9"},{"key":"2025121400544593000_11.6.e052312.10","doi-asserted-by":"publisher","DOI":"10.1177\/0269216312457214"},{"key":"2025121400544593000_11.6.e052312.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2011.07.036"},{"key":"2025121400544593000_11.6.e052312.12","first-page":"CD007503","article-title":"Antidepressants for depression in physically ill people","volume":"3","author":"Rayner","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121400544593000_11.6.e052312.13","doi-asserted-by":"publisher","DOI":"10.1177\/0269216310380764"},{"key":"2025121400544593000_11.6.e052312.14","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0112"},{"key":"2025121400544593000_11.6.e052312.15","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000246212.03530.fd"},{"key":"2025121400544593000_11.6.e052312.16","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1002\/pon.4220","article-title":"Randomized, double-blind, placebo-controlled study of methylphenidate for the treatment of depression in SSRI-treated cancer patients receiving palliative care","volume":"26","author":"Sullivan","year":"2017","journal-title":"Psychooncology"},{"key":"2025121400544593000_11.6.e052312.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2011-000093"},{"key":"2025121400544593000_11.6.e052312.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.1.335"},{"key":"2025121400544593000_11.6.e052312.19","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.28.9.455"},{"key":"2025121400544593000_11.6.e052312.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(96)71599-2"},{"key":"2025121400544593000_11.6.e052312.21","unstructured":"Miller R . Miller\u2019s Anesthesia. 7th ed. Philadelphia PA: Churchill Livingstone, 2010."},{"key":"2025121400544593000_11.6.e052312.22","doi-asserted-by":"publisher","DOI":"10.1177\/1049909112454325"},{"key":"2025121400544593000_11.6.e052312.23","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2005.8.49"},{"key":"2025121400544593000_11.6.e052312.24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/082585971002600306","article-title":"The effectiveness and adverse effects profile of \"burst\" ketamine in refractory cancer pain: The VCOG PM 1-00 study","volume":"26","author":"Jackson","year":"2010","journal-title":"J Palliat Care"},{"key":"2025121400544593000_11.6.e052312.25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.1081"},{"key":"2025121400544593000_11.6.e052312.26","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-014-3664-5"},{"key":"2025121400544593000_11.6.e052312.27","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.psym.2014.05.005","article-title":"Ketamine for the treatment of depression in patients receiving hospice care: a retrospective medical record review of thirty-one cases","volume":"56","author":"Iglewicz","year":"2015","journal-title":"Psychosomatics"},{"key":"2025121400544593000_11.6.e052312.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2014.03.026"},{"key":"2025121400544593000_11.6.e052312.29","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291714001603"},{"key":"2025121400544593000_11.6.e052312.30","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13030392"},{"key":"2025121400544593000_11.6.e052312.31","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.15040465"},{"key":"2025121400544593000_11.6.e052312.32","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1176\/appi.neuropsych.14100243","article-title":"The effect of repeated ketamine infusion over facial emotion recognition in treatment-resistant depression: a preliminary report","volume":"27","author":"Shiroma","year":"2015","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"2025121400544593000_11.6.e052312.33","first-page":"287","article-title":"Relationship of ketamine\"s antidepressant and psychotomimetic effects in unipolar depression","volume":"34","author":"Sos","year":"2013","journal-title":"Neuro Endocrinol Lett"},{"key":"2025121400544593000_11.6.e052312.34","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.8.856"},{"key":"2025121400544593000_11.6.e052312.35","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4088\/JCP.13m08852","article-title":"Ketamine safety and tolerability in clinical trials for treatment-resistant depression","volume":"76","author":"Wan","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"2025121400544593000_11.6.e052312.36","doi-asserted-by":"publisher","DOI":"10.1111\/cns.12103"},{"key":"2025121400544593000_11.6.e052312.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2012.06.022"},{"key":"2025121400544593000_11.6.e052312.38","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: a systematic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"2025121400544593000_11.6.e052312.39","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2008.9828"},{"key":"2025121400544593000_11.6.e052312.40","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2011.0314"},{"key":"2025121400544593000_11.6.e052312.41","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2012.0617"},{"key":"2025121400544593000_11.6.e052312.42","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1017\/S1478951519000580","article-title":"Ketamine as augmentation for the treatment of major depression and suicidal risk in advanced cancer: case report","volume":"18","author":"Rodr\u00edguez-Mayoral","year":"2020","journal-title":"Palliat Support Care"},{"key":"2025121400544593000_11.6.e052312.43","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1089\/jpm.2018.0627","article-title":"The efficacy of ketamine in the palliative care setting: a comprehensive review of the literature","volume":"22","author":"Goldman","year":"2019","journal-title":"J Palliat Med"},{"key":"2025121400544593000_11.6.e052312.44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.7173"},{"key":"2025121400544593000_11.6.e052312.45","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2007.0140"},{"key":"2025121400544593000_11.6.e052312.46","doi-asserted-by":"publisher","DOI":"10.1191\/026921699676753309"},{"key":"2025121400544593000_11.6.e052312.47","doi-asserted-by":"publisher","DOI":"10.1191\/0269216304pm865oa"},{"key":"2025121400544593000_11.6.e052312.48","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1071\/AH13041","article-title":"Depression in palliative care patients: a survey of assessment and treatment practices of Australian and New Zealand palliative care specialists","volume":"38","author":"Porche","year":"2014","journal-title":"Aust Health Rev"},{"key":"2025121400544593000_11.6.e052312.49","unstructured":"American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 4th ed. Washington DC: American Psychiatric Association, 1994."},{"key":"2025121400544593000_11.6.e052312.50","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604396"},{"key":"2025121400544593000_11.6.e052312.51","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2007.01103.x"},{"key":"2025121400544593000_11.6.e052312.52","doi-asserted-by":"publisher","DOI":"10.1370\/afm.1139"},{"key":"2025121400544593000_11.6.e052312.53","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.151.4.537"},{"key":"2025121400544593000_11.6.e052312.54","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1080\/13607863.2015.1078278","article-title":"Towards a new conceptualization of depression in older adult cancer patients: a review of the literature","volume":"20","author":"Saracino","year":"2016","journal-title":"Aging Ment Health"},{"key":"2025121400544593000_11.6.e052312.55","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3390\/ijerph15081758","article-title":"Core symptoms of major depressive disorder among palliative care patients","volume":"15","author":"Huey","year":"2018","journal-title":"Int J Environ Res Public Health"},{"key":"2025121400544593000_11.6.e052312.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2008.12.004"},{"key":"2025121400544593000_11.6.e052312.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2011.12.010"},{"key":"2025121400544593000_11.6.e052312.58","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyv124","article-title":"Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis","volume":"19","author":"Xu","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"key":"2025121400544593000_11.6.e052312.59","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3109\/15622975.2014.922697","article-title":"Pilot dose-response trial of i.v. ketamine in treatment-resistant depression","volume":"15","author":"Lai","year":"2014","journal-title":"World J Biol Psychiatry"},{"key":"2025121400544593000_11.6.e052312.60","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/acps.12572","article-title":"Placebo-Controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression","volume":"134","author":"Loo","year":"2016","journal-title":"Acta Psychiatr Scand"},{"key":"2025121400544593000_11.6.e052312.61","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012518831494"},{"key":"2025121400544593000_11.6.e052312.62","first-page":"58","article-title":"Dosing modifications of targeted cancer therapies in patients with special needs: evidence and controversies","volume":"81","author":"Ng","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025121400544593000_11.6.e052312.63","unstructured":"eviQ . Classi\ufb01cation of hepatic dysfunction for chemotherapy dose modi\ufb01cations. Cancer Institute NSW, 2012. https:\/\/www.eviq.org.au\/additional-clinical-information\/3248-classification-of-hepatic-dysfunction-for-che#"},{"key":"2025121400544593000_11.6.e052312.64","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.2017.74.4102","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American Society of clinical Oncology-Friends of cancer research organ dysfunction, prior or concurrent malignancy, and comorbidities Working group","volume":"35","author":"Lichtman","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025121400544593000_11.6.e052312.65","doi-asserted-by":"publisher","DOI":"10.1111\/cns.12099"},{"key":"2025121400544593000_11.6.e052312.66","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jagp.2017.06.007","article-title":"Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression","volume":"25","author":"George","year":"2017","journal-title":"Am J Geriatr Psychiatry"},{"key":"2025121400544593000_11.6.e052312.67","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jad.2016.09.008","article-title":"Continuation phase intravenous ketamine in adults with treatment-resistant depression","volume":"206","author":"Vande Voort","year":"2016","journal-title":"J Affect Disord"},{"key":"2025121400544593000_11.6.e052312.68","doi-asserted-by":"publisher","DOI":"10.1177\/0269881113478283"},{"key":"2025121400544593000_11.6.e052312.69","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(99)00044-5"},{"key":"2025121400544593000_11.6.e052312.70","first-page":"1597","article-title":"What is the evidence for mirtazapine in treating cancer-related symptomatology? A systematic review","volume":"28","author":"Economos","year":"2020","journal-title":"Support Care Cancer"},{"key":"2025121400544593000_11.6.e052312.71","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/ejhpharm-2011-000024","article-title":"A brief review on the use of antidepressants in palliative care: table 1","volume":"19","author":"Rhondali","year":"2012","journal-title":"European Journal of Hospital Pharmacy"},{"key":"2025121400544593000_11.6.e052312.72","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.2147\/NDT.S117146","article-title":"Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies","volume":"12","author":"Han","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2025121400544593000_11.6.e052312.73","unstructured":"National Cancer Institute . Common terminology criteria for adverse events (CTCAE) v4.03, 2010. Available: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf [Accessed 14 Aug 2018]."},{"key":"2025121400544593000_11.6.e052312.74","doi-asserted-by":"publisher","DOI":"10.2466\/pr0.1962.10.3.799"},{"key":"2025121400544593000_11.6.e052312.75","first-page":"97","article-title":"The brief psychiatric rating scale (BPRS): recent developments in ascertainment and scaling","volume":"24","author":"Overall","year":"1988","journal-title":"Psychopharmacology Bulletin"},{"key":"2025121400544593000_11.6.e052312.76","doi-asserted-by":"publisher","DOI":"10.1023\/A:1024465317902"},{"key":"2025121400544593000_11.6.e052312.77","unstructured":"Bremner J . The clinician administered dissociative states scale (CADSS): Instructions for administration. Emory University, 2014."},{"key":"2025121400544593000_11.6.e052312.78","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"2025121400544593000_11.6.e052312.79","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1017\/S1041610220000903","article-title":"A systematic review of ketamine for the treatment of depression among older adults","volume":"32","author":"Gupta","year":"2021","journal-title":"Int Psychogeriatr"},{"key":"2025121400544593000_11.6.e052312.80","unstructured":"Rayner L , Higginson I , Price A . The management of depression in palliative care: European clinical guidelines London: Department of Palliative Care, Policy & Rehabilitation, European Palliative Care Research Collaborative, 2010. Available: https:\/\/www.kcl.ac.uk\/cicelysaunders\/attachments\/depression-guidlines\/the-management-of-depression-in-palliative-care.pdf [Accessed 08 May 2019]."},{"key":"2025121400544593000_11.6.e052312.81","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6939-14-54"},{"key":"2025121400544593000_11.6.e052312.82","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.8.1323"},{"key":"2025121400544593000_11.6.e052312.83","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1176\/ajp.156.9.1380","article-title":"Competence of depressed patients for consent to research","volume":"156","author":"Appelbaum","year":"1999","journal-title":"Am J Psychiatry"},{"key":"2025121400544593000_11.6.e052312.84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"2025121400544593000_11.6.e052312.85","unstructured":"National Health and Medical Research Council . Management of data and information in research: a guide supporting the Australian code for the responsible conduct of research, 2019. Available: https:\/\/www.nhmrc.gov.au\/sites\/default\/files\/documents\/attachments\/Management-of-Data-and-Information-in-Research.pdf [Accessed 25 June 2020]."},{"key":"2025121400544593000_11.6.e052312.86","unstructured":"Therapeutic Goods Administration DSEB . Note for guidance on good clinical practice (CPMP\/ICH\/135\/95): annotated with TGA comments, 2000. Available: https:\/\/www.tga.gov.au\/sites\/default\/files\/ich13595an.pdf [Accessed 26 Oct 2018]."},{"key":"2025121400544593000_11.6.e052312.87","doi-asserted-by":"publisher","DOI":"10.1111\/j..2002.384.doc.x"},{"key":"2025121400544593000_11.6.e052312.88","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-3-201302050-00583"},{"key":"2025121400544593000_11.6.e052312.89","doi-asserted-by":"publisher","DOI":"10.1037\/t49981-000"},{"key":"2025121400544593000_11.6.e052312.90","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2850.2011.01735.x"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-052312","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T08:54:57Z","timestamp":1765702497000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-052312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":90,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6,28]]},"published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1136\/bmjopen-2021-052312"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-052312","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}